Summary

U.S. Companion Animal Osteoarthritis Market Summary

The U.S. companion animal osteoarthritis market size was estimated at USD 776.97 million in 2024 and is projected to reach USD 4,197.40 million by 2033, growing at a CAGR of 22.55% from 2025 to 2033. Key factors expected to drive the market include the rising prevalence of osteoarthritis, increasing R&D initiative, emerging novel treatments, and increasing awareness campaigns.

The U.S. companion animal osteoarthritis (CA OA) market is undergoing robust growth, fueled by innovation,
increased clinical awareness, and broader access to diverse treatment options. A convergence of advanced therapies,
preventive care initiatives, and owner-driven demand is reshaping how OA is managed in pets, particularly dogs. One of the most promising developments is the advancement of gene therapy, exemplified by CureLab Veterinary’s
ElenaVet, which demonstrated a remarkable 90% success rate in reducing pain and improving mobility in dogs with OA. This breakthrough highlights a shift toward disease-modifying approaches that offer longer-term benefits compared to conventional pain management therapies.

At the same time, veterinary-led awareness campaigns-as reported by DVM360-are raising the standard of care by emphasizing early detection, mobility screening, and proactive OA management. This growing clinical emphasis has led to better-informed pet owners and more timely treatment initiation, expanding the overall addressable market.
Complementing these efforts is the increasing availability of nutritional supplements specifically formulated for canine OA. The recent U.S. launch of a new supplement (DVM360) provides a non-prescription option for managing early-stage or adjunctive care, especially for cost-conscious pet owners or those seeking holistic solutions.
In parallel, regenerative therapies, such as stem cell treatments, are gaining momentum in specialty practices and progressive clinics. As outlined by Fitzpatrick Referrals, these therapies offer minimally invasive solutions that focus on joint restoration rather than symptom suppression-aligning with rising expectations for long-lasting, restorative care.

Further strengthening the market is a growing pipeline of oral therapeutics, including Can-Fite and Vetbiolix’s Piclidenoson, currently in advanced clinical development. This A3 adenosine receptor agonist is positioned to offer a convenient, non-invasive treatment option with global peak sales projected to exceed $445 million by 2034. Its progress reflects strong investor and clinical confidence in oral OA therapies as viable alternatives to injectables and NSAIDs.

In conclusion, the U.S. CA OA market is being driven by a comprehensive, multi-modal evolution-from cutting-edge gene and cell therapies to increased practitioner education and owner engagement. This diversified ecosystem improves patient outcomes and solidifies the U.S. as a global front-runner in advancing osteoarthritis care for companion animals.

U.S. Companion Animal Osteoarthritis Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. companion animal osteoarthritis market report based on product, animal, route of administration, and end use:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Biologics
o Stem Cells
o Platelet-Rich Plasma (PRP)
o Monoclonal Antibodies (mAb)
o Other Biologics
• Viscosupplements
• Pharmaceuticals
o Steroids
o NSAIDS
o Others
• Nutritional Supplements
• Animal Outlook (Revenue, USD Million, 2021 - 2033)
• Canine
• Equine
• Feline
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Oral
• Injectable
o Intra-muscular
o Intra-articular
o Other Injectable
• Topical
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Veterinary Hospitals/Clinics
• E-commerce
• Others

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.4. Information/Data Analysis
1.5. Market Formulation & Visualization
1.6. Data Validation & Publishing
1.7. Model Details
1.7.1. Commodity flow analysis
1.7.2. Country Market: CAGR Calculation
1.8. List of Secondary Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. U.S. Companion Animal Osteoarthritis Market Variable Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market
3.1.2. Ancillary Market
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising Prevalence of Osteoarthitis
3.2.1.2. Increasing R&D Initiatives
3.2.1.3. Emerging Novel Treatments
3.2.1.4. Increasing Awareness Campaigns
3.2.1.5. Advancing Diagnostic Techniques Increasing Adoption of OA Treatment
3.2.2. Market Restraint Analysis
3.2.2.1. Regulatory Hurdles
3.2.2.2. Emerging Adverse Drug Reactions (ADR)
3.2.2.3. Stringent Regulations
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenge Analysis
3.3. Companion Animal Osteoarthritis Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitution
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political & Legal landscape
3.3.2.2. Economic and Social landscape
3.3.2.3. Technological landscape
3.3.2.4. Environmental landscape
3.3.3. Regulatory Framework by Key Countries
3.3.4. Estimated Animal Population, by Key Species, 2021 - 2024
3.3.5. Pipeline/ Clinical Trials Analysis
3.3.6. COVID-19 Impact Analysis
Chapter 4. U.S. Companion Animal Osteoarthritis Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. Companion Animal Osteoarthritis Market: Product Movement Analysis
4.3. U.S. Companion Animal Osteoarthritis Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
4.4. Biologics
4.4.1. Biologics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.2. Stem Cells
4.4.2.1. Stem Cells Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3. Platelet-Rich Plasma (PRP)
4.4.3.1. Platelet-Rich Plasma (PRP) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.4. Monoclonal Antibodies (mAb)
4.4.4.1. Monoclonal Antibodies (mAb) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.5. Other Biologics
4.4.5.1. Other Biologics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Viscosupplements
4.5.1. Viscosupplements Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Pharmaceuticals
4.6.1. Pharmaceuticals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.2. Steroids
4.6.2.1. Steroids Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.3. NSAIDs
4.6.3.1. NSAIDs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.4. Others
4.6.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Nutritional Supplements
4.7.1.1. Nutritional Supplements Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. Companion Animal Osteoarthritis Market: Animal Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. Companion Animal Osteoarthritis Market: Animal Movement Analysis
5.3. U.S. Companion Animal Osteoarthritis Market Size & Trend Analysis, by animal, 2021 to 2033 (USD Million)
5.4. Canine
5.4.1. Canine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Feline
5.5.1. Feline Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Equine
5.6.1. Equine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. U.S. Companion Animal Osteoarthritis Market: By Route of Administration Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. U.S. Companion Animal Osteoarthritis Market: By Route of Administration Movement Analysis
6.3. U.S. Companion Animal Osteoarthritis Market Size & Trend Analysis, by route of administration, 2021 to 2033 (USD Million)
6.3.1. Oral
6.3.1.1. Oral Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.2. Injectables
6.3.2.1. Injectables Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.3. Intra-muscular
6.3.3.1. Intra-muscular Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.4. Intra-articular
6.3.4.1. Intra-articular Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.5. Other Injectables
6.3.5.1. Other Injectables Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.6. Others
6.3.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. U.S. Companion Animal Osteoarthritis Market: By End Use Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. U.S. Companion Animal Osteoarthritis Market: By End Use Movement Analysis
7.3. U.S. Companion Animal Osteoarthritis Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
7.3.1. Veterinary Hospitals/Clinics
7.3.1.1. Veterinary Hospitals/Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.2. E-commerce
7.3.2.1. E-commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.3. Others
7.3.3.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.2. Company Market Position Analysis/ Heap Map Analysis
8.3. Company Profiles
8.3.1. Zoetis Inc.
8.3.1.1. Participant’s Overview
8.3.1.2. Financial Performance
8.3.1.3. Product Benchmarking
8.3.1.4. Strategic Initiatives
8.3.2. Boehringer Ingelheim
8.3.2.1. Participant’s Overview
8.3.2.2. Financial Performance
8.3.2.3. Product Benchmarking
8.3.2.4. Strategic Initiatives
8.3.3. Elanco Animal Health
8.3.3.1. Participant’s Overview
8.3.3.2. Financial Performance
8.3.3.3. Product Benchmarking
8.3.3.4. Strategic Initiatives
8.3.4. American Regent, Inc.
8.3.4.1. Participant’s Overview
8.3.4.2. Financial Performance
8.3.4.3. Product Benchmarking
8.3.4.4. Strategic Initiatives
8.3.5. Merck Animal Health (Merck & Co. Inc)
8.3.5.1. Participant’s Overview
8.3.5.2. Financial Performance
8.3.5.3. Product Benchmarking
8.3.5.4. Strategic Initiatives
8.3.6. Vetoquinol S.A.
8.3.6.1. Participant’s Overview
8.3.6.2. Financial Performance
8.3.6.3. Product Benchmarking
8.3.6.4. Strategic Initiatives
8.3.7. Ceva Sante Animale
8.3.7.1. Participant’s Overview
8.3.7.2. Financial Performance
8.3.7.3. Product Benchmarking
8.3.7.4. Strategic Initiatives
8.3.8. Virbac
8.3.8.1. Participant’s Overview
8.3.8.2. Financial Performance
8.3.8.3. Product Benchmarking
8.3.8.4. Strategic Initiatives
8.3.9. Biogenesis Bago
8.3.9.1. Participant’s Overview
8.3.9.2. Financial Performance
8.3.9.3. Product Benchmarking
8.3.9.4. Strategic Initiatives
8.3.10. Ardent Animal Health, LLC
8.3.10.1. Participant’s Overview
8.3.10.2. Financial Performance
8.3.10.3. Product Benchmarking
8.3.10.4. Strategic Initiatives
8.3.11. PetVivo Holdings, Inc. (Spryng)
8.3.11.1. Participant’s Overview
8.3.11.2. Financial Performance
8.3.11.3. Product Benchmarking
8.3.11.4. Strategic Initiatives
8.3.12. Vet Stem Inc.
8.3.12.1. Participant’s Overview
8.3.12.2. Financial Performance
8.3.12.3. Product Benchmarking
8.3.12.4. Strategic Initiatives
8.3.13. Enso Discoveries
8.3.13.1. Participant’s Overview
8.3.13.2. Financial Performance
8.3.13.3. Product Benchmarking
8.3.13.4. Strategic Initiatives
8.3.14. Contura Vet US
8.3.14.1. Participant’s Overview
8.3.14.2. Financial Performance
8.3.14.3. Product Benchmarking
8.3.14.4. Strategic Initiatives
8.3.15. T-Cyte Therapeutics
8.3.15.1. Participant’s Overview
8.3.15.2. Financial Performance
8.3.15.3. Product Benchmarking
8.3.15.4. Strategic Initiatives
8.3.16. Medrego LLC.
8.3.16.1. Participant’s Overview
8.3.16.2. Financial Performance
8.3.16.3. Product Benchmarking
8.3.16.4. Strategic Initiatives
8.4. Strategy Mapping
8.4.1.1. Mergers & Acquisitions
8.4.1.2. Partnerships & Collaborations
8.4.1.3. Expansion
8.4.1.4. Product launch
8.4.1.5. Product Approval
8.4.1.6. Others
8.5. List of Key Companies
8.5.1.1. List of Manufacturers
8.5.1.2. List of Distributors